Page 4 - Graybug Vision News Today

Shares of Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target […]

Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 75,100 shares, a decrease of 19.6% from the February 28th total of 93,400 shares. Based on an average trading volume of 89,300 shares, the short-interest ratio is presently 0.8 days. […]

/PRNewswire/ -- DelveInsights Food Allergy Market Insights report proffers a detailed comprehension of Food Allergy market size by treatment, epidemiology,...

- The recent launch of Aimmune's Palforzia has paved the way for other key players to invest in the food allergy treatment market landscape. Further, the FDA-approved fast track designation

BALTIMORE, Jan. 20, 2022 -- Graybug Vision, Inc. , a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic... | January 20, 2022

Ocular Drug Delivery Technology Market to Witness Revolutionary Growth by 2026 | Alimera Sciences, EyeGate Pharma, Graybug Vision

MINNEAPOLIS--(BUSINESS WIRE)--Jul 15, 2021-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the election of two industry veterans to the Company’s Board of Directors. Amy Burroughs, President and CEO of Cleave Therapeutics, brings over 20 years of experience in business and commercial development, strategy and leadership in the pharmaceutical indust...

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn’t stop the ...

/PRNewswire/ -- DelveInsights Age-related Vision Dysfunction Market, Epidemiology and Market Forecast-2030 report presents a holistic picture of the...